Use of Ozone-Depleting Substances:

 
CONTENT

Federal Register: September 17, 2010 (Volume 75, Number 180)

Rules and Regulations

Page 56858

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr17se10-3

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration 21 CFR Part 2

Docket No. FDA-2006-N-0304

(formerly Docket No. 2006N-0262)

RIN 0910-AF93

Use of Ozone-Depleting Substances; Removal of Essential-Use

Designation (Flunisolide, etc.); Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of April 14, 2010 (75 FR 19213). The document amended FDA's regulation on the use of ozone- depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers

(MDIs). The document was published with an inadvertent error. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Diane Sullivan, Office of Policy,

Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3210, Silver Spring, MD 20993, 301-796-9171.

SUPPLEMENTARY INFORMATION: In FR Doc. 2010-8467, appearing on page 19213, in the Federal Register of Wednesday, April 14, 2010, the following correction is made: 1. On page 19213, in the third column, the heading ``RIN 0910-

AF92'' is corrected to read ``RIN 0910-AF93''.

Dated: September 13, 2010.

David Dorsey,

Acting Deputy Commissioner for Policy, Planning and Budget.

FR Doc. 2010-23195 Filed 9-16-10; 8:45 am

BILLING CODE 4160-01-S